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Bilateral Vertebral Venous sinus 
thrombosis Causing Cervical spinal 
Cord Compression in a Dog
Kathryn E. Rhue, Amanda R. Taylor, Robert C. Cole and Randolph L. Winter*
Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL, USA
A 10-year-old male neutered mixed breed dog was evaluated for cervical hyperesthesia 
and tetraparesis. Magnetic resonance imaging of the brain and cervical spinal cord 
identified an extradural compressive lesion over the body of C2 caused by marked 
dilation of the vertebral venous sinuses. Following intravenous contrast administration 
both vertebral sinuses had heterogeneous contrast enhancement consistent with 
incomplete thrombi formation. An abdominal ultrasound also showed a distal aortic 
thrombus. A definitive cause for the thrombi formation was not identified, but the patient 
had several predisposing factors which may have contributed. The patient was treated 
with a combination of warfarin, clopidogrel, and enoxaparin as well as analgesics. Within 
48 h of initiation of warfarin therapy, the tetraparesis and hyperesthesia were markedly 
improved. Repeat abdominal ultrasound 3  weeks after discharge showed reduction 
in size of aortic thrombus. Neurologic function remained normal for 6 weeks following 
initiation of treatment. Seventy-four days following initial diagnosis the patient rapidly 
declined and passed away at home. Necropsy was declined. This is the first report of 
vertebral venous sinus enlargement leading to spinal cord compression and tetraparesis 
in a dog. Additionally, warfarin in combination with clopidogrel and enoxaparin appeared 
to be a safe and effective treatment for the suspected thrombi reported in this case. 
Vertebral sinus enlargement secondary to thrombi should be considered as a differential 
diagnosis in patients presenting with tetraparesis and cervical hyperesthesia.
Keywords: thrombus, tetraparesis, coagulation, warfarin, MRI
INtRoDUCtIoN
A 10-year-old male, neutered [18.8 kg (41.36 lb)] mixed breed dog was referred for evaluation of 
a 9-day history of cervical hyperesthesia. Nine days prior to presentation, the dog was trembling 
and was unwilling to move his neck or shake his head. The following day, the dog presented 
to his primary care veterinarian where his chronic prednisone (prednisone tablets 10  mg, 
Qualitest Pharmaceuticals, Huntsville, AL, USA) dosage was increased (from 0.27  mg/kg PO 
q12h to 0.53 mg/kg PO q12h) and tramadol (tramadol tablets 50 mg, Amneal Pharmaceuticals, 
Bridgewater, NJ, USA) (2.7 mg/kg PO q12h) was prescribed for cervical hyperesthesia. Due to a 
Abbreviations: ALKP, alkaline phosphatase; ALT, alanine transferase; aPTT, activated partial thromboplastin time; AST, aspar-
tate aminotransferase; CSF, cerebrospinal fluid; CVT, cerebral venous thrombosis; INR, international normalized ratio; MFS, 
modified Frankel score; MRI, magnetic resonance imaging; PLN, protein-losing nephropathy; SIRS, systemic inflammatory 
response syndrome; UPC, urine protein:creatinine ratio; vWF, von Willebrand factor.
FIGURe 1 | Left parasagittal images in (a) t2, (B) t1, and (C) t1 + C 
weighting. These depict the enlargement of the vertebral venous plexus/
sinus resulting in the compression and dorsal elevation of the spinal cord. 
Enlargement of this plexus is present from the cranial aspect of C2 to the 
caudal aspect of C6.
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lack of improvement after 48 h, the prednisone dose (1.1 mg/
kg PO q12h) and tramadol dose frequency (2.7 mg/kg PO q8h) 
were increased. The dog’s cervical mobility improved, but his 
cervical hyperesthesia did not improve. The dog was referred 
for further evaluation.
The dog’s previous history included occasional generalized 
seizures of unknown etiology beginning 4 years prior to pres-
entation, suspected inflammatory bowel disease, proteinuria 
[urine protein:creatinine ratio (UPC) 1.25], and decreased 
hepatic function. The therapy for seizure activity included 
extended release levetiracetam (levetiracetam extended 
release tablets 500 mg, Watson Pharmaceuticals, Corona, CA, 
USA) (106 mg/kg PO q12h), zonisamide (zonisamide capsules 
100 mg, Glenmark, Mahwah, NJ, USA) (16 mg/kg PO q12h), 
potassium bromide (potassium bromide oral solution 250 mg/
mL, Letco Medical, Decatur, AL, USA) (33.2 mg/kg PO q24h), 
topiramate (topiramate tablets, Topamax, 100  mg, Janssen 
Pharmaceuticals, Raritan, NJ, USA) (10.6  mg/kg PO q8h), 
gabapentin (gabapentin capsules 300 mg, Ascend Laboratories, 
Parsippany, NJ, USA) (18.6 mg/kg PO q6h), and clorazepate 
(clorazepate tablets, 7.5  mg, Mylan Pharmaceuticals Inc., 
Rockford, IL, USA) (0.8 mg/kg PO q8h during breakthrough 
seizures). Therapy for the suspected inflammatory bowel 
disease included a 1-year duration of prednisone use (0.27–
0.53  mg/kg PO q12-24h), omeprazole (omeprazole capsules 
20  mg, Sandoz Pharmaceuticals, Rotkreuz, Switzerland) 
(1.1 mg/kg PO q24h), and a hypoallergenic diet [Hill’s Science 
Diet Z/D (Hill’s Prescription Diet Z/D Dry dog food 25 lb, Hill’s 
Nutrition, Topeka, KS, USA)]. Hepatic dysfunction was sus-
pected, but not confirmed, to be related to previous long-term 
phenobarbital use; patient was on phenobarbital for 4  years 
and this was discontinued 6  months prior to presentation. 
Therapy for suspected hepatic dysfunction included ursodiol 
(ursodiol tablets 250 mg, Par Pharmaceutical, Chestnut Ridge, 
NY, USA) (13.9  mg/kg PO q24h), Denamarin (Denamarin 
tablets 425 mg, Nutramax Laboratories, Lancaster, SC, USA) 
(22.6  mg/kg PO q24h), lactulose (lactulose oral suspension 
10 g/15 ml, Qualitest Pharmaceuticals, Huntsville, AL, USA) 
(0.8  mg/kg PO q8h), and milk thistle (milk thistle capsules, 
140  mg, NaturesMade, Mission Hills, CA, USA) (dosage 
unknown) three times daily.
On presentation, the dog was depressed with low head and 
tail carriage, moderate generalized ataxia/tetraparesis, and a 
wide-based stance in the pelvic limbs. Femoral pulse strength 
was mildly decreased bilaterally, and severe hepatomegaly was 
observed on abdominal palpation. Neurologic exam identified 
decreased postural reactions in all limbs with notable generalized 
muscle atrophy and marked cervical hyperesthesia. The cranial 
nerve exam was normal other than a mild left-sided head tilt, and 
muscle wasting of the muscles of mastication. Segmental spinal 
reflexes were normal. The patient was classified as ambulatory 
tetraparetic with a neuroanatomic localization of spinal cord seg-
ments C1–C5 and a modified Frankel score of 4. The CBC was 
consistent with a stress leukogram, and a serum chemistry panel 
had elevated liver enzymes (ALKP 3,886  U/L ref 14–152  U/L, 
alanine transferase 496  U/L ref 13–151  U/L, aspartate ami-
notransferase 70  U/L ref 18–55  U/L), mild hypoalbuminemia 
[27  g/L, ref 30–43  g/L (2.7  mg/dL, ref 3.0–4.3  mg/dL)], and 
hypercholesterolemia [20.27 mmol/L, ref 3.41–8.66 (784 mg/dL 
ref 132–335)].
Imaging studies performed included thoracic and cervical 
radiography along with magnetic resonance imaging (MRI) 
(Philips Infinion 1.5T, Philips Medical Systems, Cleveland, 
OH, USA) of the brain and cervical region performed under 
general anesthesia. The thoracic and cervical radiographs were 
considered to be unremarkable for the patient’s age and breed. 
MRI sequences included T1- and T2-weighted fast spin echo 
in both sagittal and transverse planes (TR 633–876, TE 98, TR 
4,000–8,000, TE 117–118, respectively), transverse T2* (TR 800, 
TE 23.5), sagittal short T1 inversion recovery (TR 4,000, TE 16.8), 
sagittal half Fourier acquisition single shot turbo spin echo (TR 
40,000, TE 616), postgadolinium (ProHance injectable, 279.3 mg/
mL, Bracco Diagnostics, Monroe Township, NJ, USA) (0.1 mmol/
kg) T1 fast spin echo in both sagittal and transverse planes (TR 
633–876, TE 9.8). Magnetic resonance angiography was acquired 
using both 2D (TR 5,569, TE 118.3) and 3D time of flight tech-
niques (3D Sliding Interleaved Ky-single interleaved ky TR 27, 
TE 6.7) and reformatted using maximum intensity projection. 
MRI of the brain and cervical spinal cord identified an extradural 
compressive lesion over the body of C2 (Figure 1) and extending 
cranially on both sides of the spinal cord to cranial aspect of C1. 
On transverse sequences, moderate spinal cord compression was 
associated with marked dilation of the vertebral venous sinuses 
(Figure 2). At the mid body of C1, both sinuses were hypointense 
on T2, and iso to hyperintense on T1 (Figure 2). The same area 
FIGURe 3 | Reconstruction of the vertebral venous plexus (asterisks), 
vertebral veins (arrowheads), and internal carotid arteries (arrows). 
The intensity of the red signal indicates contrast enhancement, while the blue 
signal is less contrast enhanced. The heterogeneity of the blue signal in the 
plexus indicates heterogenous material in the sinus or turbulent flow.
FIGURe 2 | transverse images at the level of the mid body of C2, in (a) t2, (B) t2*, (C) t1, and (D) t1 + C weighting. The arrow indicates the signal void 
on the T2* image.
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showed a signal void on T2*. Extending caudally to the mid 
body of C2 at the site of maximal dilation of the vertebral venous 
sinuses, the signal pattern was heterogenous on T2*, T2, and more 
uniform hyperintense signal on T1 (Figure 2). Postgadolinium, 
there was minimal enhancement noted in the right vertebral 
venous sinus (Figures 2 and 3). A mild disk protrusion was also 
noted at C2–C3 with no spinal cord compression. The remainder 
of the cervical spinal cord and brain were considered to be within 
normal limits. Based on the moderate spinal cord compression 
associated with the venous sinus enlargement and the relative lack 
of compression associated with the disk protrusion at C2–C3, the 
vertebral sinus enlargement was thought to be the cause of the 
patient’s clinical signs. The changes in the vertebral sinuses were 
suggestive of incompletely formed thrombi in both the left and 
right vertebral sinuses at the level of C1 with subsequent dilation 
of the sinuses at the level of C2 (Figure 3). The signal pattern of 
a venous thrombus is similar to that of parenchymal hemorrhage 
and is dependent on the age of the thrombus. The changes in 
signal intensity are thought to be related to the paramagnetic 
effects of hemoglobin breakdown in the thrombus. The T1 hyper-
intensity and predominantly T2 hypointensity were consistent 
with a subacute thrombus (6–15 days) (1). Although the changes 
noted were suggestive of venous thrombosis, slow or turbulent 
flow can cause a similar signal change on spin echo sequences. 
Because of this, T2* was acquired in the transverse plane. This 
sequence has been shown to have higher sensitivity to magnetic 
susceptibility effects of blood products and can improve detection 
of intravascular clots (2, 3). The formation of deoxyhemoglobin 
produces a non-uniform magnetic field with a rapid dephasing of 
proton spins and subsequent loss of T2* weighted signal as was 
seen in this case (2, 3). A definitive cause of the suspected thrombi 
was not identified on MRI.
A lumbar cerebrospinal fluid sample was consistent with 
albuminocytologic dissociation and minimal blood contamina-
tion (0 nucleated cells/μL, 3 red blood cells/μL, protein 92.9 mg/
dL). Serum samples were submitted for Neospora caninum, 
Toxoplasma gondii, Erhlichia canis, Rickettsia rickettsii, and 
Cryptococcus neoformans antibody testing as well as aspergillosis 
EIA antigen testing (Platelia Aspergillus, MiraVista Laboratories, 
Indianapolis, IN, USA). A urine sample was also submitted for 
canine distemper virus PCR. The T. gondii IgG titer was posi-
tive at 1:320 (reference <1:40), while the IgM titer was negative. 
The aspergillosis EIA galactomannan antigen test was weakly 
positive (0.77 index; ≥0.5 positive), though it was later noted that 
the patient had been treated with plasmalyte-A (plasmalyte-A, 
Baxter Healthcare Corporation, Deerfield, IL, USA) which 
has been known to cause a false positive with this test (4). 
Abdominal ultrasonography (Phillips IE33, Phillips Medical 
Systems, Cleveland, OH, USA) was performed which identified a 
1.1 cm × 0.4 cm hyperechoic structure in the distal aorta between 
the origin of the external and internal iliac arteries with devia-
tion of blood flow around the structure. This was diagnosed as an 
aortic thrombus. Other findings included marked hepatomegaly 
with increased echogenicity diffusely and multiple pinpoint 
hyperechoic foci with numerous ill-defined hypoechoic nodules. 
Moderate degenerative changes were noted in both kidneys but 
there was adequate blood flow to each kidney. Echogenic debris 
was present in the urinary bladder. The changes in the liver were 
consistent with vacuolar hepatopathy and regenerative nodules 
with the pinpoint foci representing mineral deposits, though 
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other differentials could not be excluded. No other significant 
abnormalities were noted.
A urinalysis revealed proteinuria [3,430  g/L (343  mg/dL)], 
mild hematuria, 10–20  WBC/hpf, and many rod bacteria. 
A urine culture was positive with heavy growth of Escherichia coli 
(>100,000 col/ml). A coagulation profile had a mild thrombocyto-
sis (538 × 109/L, ref 152–518 × 109/L), minor increase in activated 
partial thromboplastin time (14.6 s, ref 11.6–14.0), hyperfibrino-
genemia [9.70 μmol/L, ref 2.97–4.59 μmol/L (329.9 mg/dL, ref 
101–156)], mild decrease in antithrombin (129%, ref >150), and 
a minor increase in d-dimers (250–500, ref <250). The prothrom-
bin time, plasma fibrin degradation products, and mean platelet 
volume were within normal reference intervals.
Antithrombotic therapy was initiated with warfarin (warfarin 
sodium tablets 1  mg, Exelan Pharmaceuticals, Lawrenceville, 
GA, USA) (0.05  mg/kg PO q24h), clopridogrel (clopidogrel 
tablets 75  mg, Aurobindo USA, Dayton, NJ, USA) (2  mg/
kg PO q24h), and enoxaparin (enoxaparin injection 100  mg/
mL, Sandoz Pharmaceuticals, Rotkreuz, Switzerland) (0.8  U/
kg SQ q6h). Tramadol was discontinued and the dog was 
placed on methadone (methadone injectable 10 mg/mL, Mylan 
Pharmaceuticals Inc., Rockford, IL, USA) (0.2 mg/kg IV q6h), 
amantadine (amantadine hydrochloride capsules 100  mg, 
Upsher-Smith Pharmaceuticals, Maple Grove, MN, USA) 
(2.6 mg/kg PO q12h), and a fentanyl patch (fentanyl transdermal 
patch 75 μg/h, Apotex, ON, Canada) (4 μg/kg) for pain control. 
Within 24 h, the methadone was discontinued, and in 48 h the 
enoxaparin was discontinued. Approximately 48  h following 
initiation of antithrombotic therapy, the dog’s ataxia markedly 
improved. Additionally, there were only extremely mild postural 
reaction deficits present in all four limbs and his femoral pulses 
were subjectively stronger.
Over the following month, the dog’s neurologic function 
and treatment remained fairly static other than weekly adjust-
ments to the warfarin dose based on repeated international 
normalized ratios (INRs). The warfarin dose was changed as 
previously described, with a goal INR of 2.0–3.0 (5). There were 
also changes in lactulose administration based on increases 
in plasma ammonia. Severe proteinuria [3,570–4,910  g/L 
(357–491 mg/dL)] persisted after resolution of the urinary tract 
infection. The dog’s pain remained controlled with amantadine 
and fentanyl; 10  days after initiating treatment, the fentanyl 
was changed to tramadol. Approximately 3  weeks after initial 
discharge, a T. gondii titer was repeated and was consistent 
with active infection (increase to 1:1,280), so treatment with 
clindamycin (clindamycin capsules, 75  mg, 150  mg, Lannett 
Pharmaceuticals, Philadelphia, PA, USA) (12 mg/kg PO q12h) 
was initiated. An abdominal ultrasound was also repeated 
which documented a decrease in the size of the aortic thrombus 
(0.96 cm × 0.25 cm). The remainder of the ultrasound was oth-
erwise unchanged from the previous exam. An MRI was offered 
to document any changes in the vertebral venous thromboses, 
but was declined by the owner.
Over the following weeks, the patient developed worsening 
of his previously diagnosed hepatic dysfunction which resulted 
in hepatic encephalopathy. This required increases in lactulose 
dose and the transient addition of neomycin (neomycin sulfate 
oral liquid 200 mg/mL, MWI Veterinary Supply, Boise, ID, USA) 
(9.5 mg/kg PO q12h). Episodes of minor bleeding from the gums 
and minor wounds developed approximately 6 weeks after initiat-
ing warfarin though signs resolved with a decrease in dose. The 
signs associated with the cervical myelopathy remained resolved 
6  weeks after initiation of antithrombotic therapy. On day 74 
following diagnosis of the thrombi, the patient was reported to 
be lethargic and inappetent. Evaluation by a veterinarian was 
recommended but declined, and the patient passed away at home 
within 24 h. A necropsy was declined.
Best veterinary care was practiced in the diagnosis and treat-
ment of this patient and owner consent was obtained for all pro-
cedures prior to their performance. No experimental protocols 
were utilized for the diagnosis or treatment of this patient so an 
institutional review was not required or performed.
BaCKGRoUND
Reports of thromboses causing neurologic dysfunction mostly 
involve cerebral venous thrombosis (CVT), and these are 
uncommon in the human literature accounting for <1% of all 
strokes (6, 7). Vertebral venous thrombosis appears even more 
rare, with no reports in the veterinary literature and the reports 
published in the human literature are only vaguely similar to 
the case reported herein (8–12). Vertebral artery thrombosis, 
vertebral artery aneurysm, and vertebral arteriovenous malfor-
mation with thrombosis have been associated with neurologic 
dysfunction in human patients (8–10), and chronic myelopathy 
with concurrent vertebral and spinal artery thromboses in a 
dog has also been reported (13). Enlargement of the vertebral 
sinuses have also been associated with neurologic dysfunction 
and spinal cord compression in human patients (8). One case 
describes back pain associated with a vertebral sinus hematoma 
(10), whereas another case series of 13 human patients described 
radiculopathy and chronic back pain caused by epidural venous 
enlargement (12). Several factors have been identified as pre-
disposing conditions for central nervous system thromboses 
including vascular wall injury (8), thrombophilias (6, 7), inflam-
matory bowel disease (6), head trauma (6), infection (6, 7), 
vasculitis and other systemic inflammatory diseases (7), cancer 
(7), and dehydration (6). Vascular malformations (10, 12), iliac 
or vena caval thrombosis (10, 12), spinal cord compression (10), 
intracranial hypotension (12), and portal hypertension (12) have 
been identified as risk factors for epidural venous enlargement. 
In the veterinary literature, vertebral venous thrombosis has not 
been reported, though there are sparse case reports of central 
nervous thromboses associated with meningeal infection (14), 
head trauma (14), a potential genetic predisposition (13), or 
idiopathic CVT (14).
This case is the first report of suspected thrombi in the ver-
tebral venous sinuses of a dog leading to clinically significant 
cervical pain and ambulatory tetraparesis. The patient also had 
a thrombus in the distal aorta and responded well to antithrom-
botic therapy including warfarin. Chronic steroid administration, 
protein-losing nephropathy (PLN), and hepatic dysfunction 
were considered possible multifactorial causes of the thrombus 
formation.
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DIsCUssIoN
Chronic steroid use can create a hypofibrinolytic state (15), 
damage to the vascular endothelium, hypercoagulability (16), 
increased platelet activation (16), decreased antithrombin activity 
(16), and hyperfibrinogenemia (15); all of which may contribute 
to thrombosis. Dogs with PLN may be hypercoagulable, as 6-22% 
of dogs with PLN have had a documented thrombotic event (17, 
18). The pathogenesis is likely multifactorial (18) with urinary 
loss of antithrombin (17, 19, 20), platelet hyperaggregability (18, 
20), interactions between platelets and fibrin (18), and endothe-
lial cell injury (19) all implicated in this disease process. Based 
on documentation of an elevated UPC prior to presentation for 
cervical hyperesthesia, as well as hypoalbuminemia and sever-
ity of proteinuria even following resolution of the documented 
urinary tract infection, the patient was suspected as having a 
PLN which may also have contributed to thrombosis. Hepatic 
dysfunction may have also contributed to thrombosis in this 
dog, as patients with liver disease may be hypercoagulable due 
to decreased activity of factor Va and factor VIIIa and decreased 
antithrombin production (21–23). Despite the many coagulation 
abnormalities associated with hepatobiliary disease, thrombosis 
is rare and usually precipitated by another factor, such as corticos-
teroid administration or PLN, shifting the balance of coagulation 
in favor of thrombi formation (21).
Toxoplasmosis may have contributed to thrombosis forma-
tion in this patient. This patient was apparently infected with 
T. gondii, which has been reported to cause cutaneous throm-
bosis in a single case (24). Even though toxoplasmosis is not 
typically associated with thrombosis, it is an inflammatory pro-
cess associated with cell necrosis in various cell types including 
brain, liver, lungs, and skeletal muscle (25). The contribution of 
toxoplasmosis if any to the thrombosis is unknown. This patient 
also had a positive aspergillosis result, which has been reported 
with cavernous sinus syndrome and CVT in humans (26). 
Typically dogs with aspergillosis have high titers (>4.0) (27). 
Based on the mild elevation reported and the previous treatment 
with plasmalyte-A, the aspergillosis test result is likely a false 
positive. Ideally a follow-up aspergillosis titer would have been 
performed 3–4 weeks following discharge from the hospital, but 
this was declined.
Aortic thrombi are documented in dogs for many causes, 
but the most common etiologies include hyperadrenocorticism 
(5, 28), PLN/protein-losing enteropathy (5), hypothyroidism 
(5), neoplasia (5, 28), and recent steroid administration (5, 28). 
Warfarin has been reported as a successful treatment for aortic 
thrombosis in the dog (5) and likely contributed to the improve-
ment in cervical pain and tetraparesis noted, given the positive 
response within several days of initiating warfarin therapy. 
Warfarin is a vitamin-K antagonist used for several decades to 
treat thrombosis in humans (29). Whereas its use in human 
medicine is frequent, reports of its use in veterinary medicine are 
rare (5, 29). Several reports (5, 28) have documented warfarin in 
the treatment of aortic thrombosis with success. To the authors’ 
knowledge, this is the first report on the use of antithrombotic 
therapy including warfarin to treat a vertebral venous throm-
bus in a dog. It is unknown if the episodes of minor bleeding 
experienced were due to warfarin therapy, or a worsening of 
the patient’s liver function which was occurring concurrently. 
Regardless, the bleeding was mild and stopped with a decrease in 
warfarin dose. Additionally, the patient was receiving clopidogrel 
which may have contributed to the mild bleeding. Further studies 
are needed documenting the safety and efficacy of warfarin for 
the treatment of venous thrombosis.
Although a repeat MRI or necropsy would have identified if the 
vertebral venous sinus thromboses had resolved, the documented 
decrease in the size of the aortic thrombus indicated successful 
antithrombotic therapy. Additionally, the improvement in neuro-
logic function, resolution of ataxia, and resolution of ambulatory 
dysfunction noted with anticoagulant therapy supports that the 
vertebral sinus enlargement and subsequent spinal cord compres-
sion was caused by bilateral thrombosis. Little information is 
known regarding the dog’s death, and it is therefore unknown if 
this was related to neurologic disease. Histopathological confir-
mation of the presumed vertebral venous and aortic thromboses 
was not obtained. It is unknown if the vertebral venous enlarge-
ment was a condition that preexisted the presumed thromboses 
of these vessels. Though a definitive cause for the thrombosis 
in this report was not identified, in up to 58% of cases (5), no 
concurrent condition is found as a cause of aortic thrombosis.
CoNCLUDING ReMaRKs
Based on the findings in this report, vertebral venous thrombosis 
should be considered as a cause for cervical hyperesthesia and 
tetraparesis in dogs predisposed to thrombosis. Additionally, 
warfarin could be a useful component of therapy for similar 
cases, though further studies are needed to determine efficacy 
and treatment length.
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This case report describes the clinical management of a dog 
according to current standard of care. All diagnostic testing and 
medical management were approved by the dog’s owner.
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